SecBot SecBot
8-K ·Filed Jun 17, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed5mo ago SEC0001818794-26-000003
8-K material event: Items 1.01
Actionable Insight • Neutral

The borrowing extends Dyne's cash runway ahead of clinical catalysts, but the IP collateral and covenant structure warrant monitoring. With $200M drawn and $200M additional capacity tied to milestones/lender approval, the trajectory of the pipeline (muscle disease programs) determines future drawdowns. Watch for next clinical data readouts and any exercise of the $75M discretionary tranche, discretionary lender approval could signal credit concern if DYN delays.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$19.20
T+0 close · Jun 17, 2026 · via day close
Latest settled
−5.16%
T+60 · $18.21
Vs SPY
−8.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 17 $19.20entry
  2. T+1 · 5mo ago +3.13%α +2.34% · $19.80
  3. T+5 · 5mo ago +5.89%α +6.93% · $20.33
  4. T+20 · 4mo ago +18.33%α +17.02% · $22.72
  5. T+60 · 2mo ago −5.16%α −8.30% · $18.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dyne Therapeutics expanded its Hercules Capital debt facility to $400M via a Second Amendment, borrowing an additional $50M on closing. The amendment adds two new $50M tranches and increases the final tranche by $25M, while reducing the minimum cash covenant from 60% to 40% of outstanding obligations and pushing the testing date from January 2027 to July 2027 (extendable to 2028). Outstanding debt post-borrowing is $200M, with up to $200M in additional undrawn tranches available upon milestones or lender approval. The move extends cash runway for a pre-revenue biotech with a $3.0B market cap and 85% analyst buy rating, but adds leverage and secured IP collateral, net neutral for the credit story.

Key Financial Metrics

Deal Type
credit_facility

Key Facts

  • Debt facility expanded to an aggregate of up to $400.0 million (from $325M prior structure)
  • Second Amendment added two $50M tranches and increased the final tranche by $25M
  • Borrowed $50.0 million on the Amendment Closing Date (June 16, 2026)
  • Outstanding principal after borrowing: $200.0 million
  • Undrawn capacity: $125M (milestone-based) + $75M (lender discretion) = up to $200M
  • Minimum cash covenant reduced from 60% to 40% of outstanding obligations, tested only if market cap < $1.65B
  • Initial cash covenant testing date moved from Jan 1, 2027 to Jul 1, 2027 (extendable to Jul 1, 2028)
  • Interest rate: WSJ Prime + 2.45% with 7.50% floor; interest-only until Jul 1, 2029 (extendable to maturity)
  • Maturity date: July 1, 2030
  • First-priority security interest on substantially all assets, including IP

Financial Impact

Added $50M cash to balance sheet with $200M drawn total and $200M additional accordion; interest cost ~10.0% (Prime ~7.5% + 2.45%). No revenue or earnings impact reported.

debtcash_runwayinterest_expenseleverage

Risk Factors

  • Interest rate exposure: floating rate with 7.50% floor could increase costs if Prime rises
  • IP collateral: first-priority security interest on all IP means lenders have edge in distress
  • Milestone dependence: $125M of undrawn tranches requires clinical/regulatory/commercial milestones, delays could limit access to capital
  • Pandemic/clinical risk: pre-revenue biotech with no approved products; stock price volatility could trigger minimum cash covenant (tested only if mkt cap < $1.65B)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001818794-26-000003
Document: 0001818794-26-000003-index-headers.html0001818794-26-000003
Document: 0001818794-26-000003-index.html0001818794-26-000003
Document: 0001818794-26-000003.txt0001818794-26-000003

Track record

54 reports on DYN

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 17, 2026